International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com,
announced today the commercial launch of its innovative line of topical
skin care products by the company's wholly-owned subsidiary, Lifeline
Skin Care ™ (www.lifelineskincare.com).
Containing extracts from human "parthenogenetic" stem cells (hpSC), the
products were formulated by a team of ISCO's research scientists in
collaboration with cosmetic formulation experts to create an advanced
scientific approach to skin care. The patent pending serums, which come
in separate formulations for day and night time use, have been safety
tested by highly regarded, independent laboratories, and have been shown
to promote anti-aging of the skin.
The initial launch of the serums is to a pre-existing list of interested
parties. We expect that the products will be available to the general
public via our online store www.lifelineskincare.com
in the near future.
A key innovation in creating the Lifeline Skin Care™ serums was the
encapsulation of the parthenogenetic stem cell extracts into
nanospheres, which not only protect the proteins, but substantially
enhance the effectiveness of the serums. World renowned skin cream
formulation experts assisted ISCO's scientists to create the finished
products and ensure that the final serums deliver the most up-to-date
advances in skin rejuvenation technology that also helps to prevent and
repair damage caused by the environment.
According to Gregory S. Keller, MD, FACS (2007 Specialist of the Year in
Facial Cosmetic Surgery in Strathmore's "Who's Who"): "These new day and
night serums represent a huge step forward in anti-aging skin care
products. Combining liposome-encapsulated proteins derived from ISCO's
powerful new class human stem cells with a unique blend of
anti-oxidants, vitamins and natural extracts, allowed Lifeline Skin Care
to create highly effective stem cell-based serums that provide strong
anti-aging benefits."
The new skin rejuvenation serums are based on the breakthrough discovery
that certain proteins derived from ISCO's proprietary pluripotent human
parthenogenetic stem cells are beneficial to the culture of human skin
cells in the laboratory. ISCO, the world leader in human parthenogenetic
stem cell technology, is studying this new class of stem cells, and has
demonstrated their therapeutic potential in many fields of regenerative
medicine. Human parthenogenetic stem cells are created from unfertilized
human eggs and do not involve any harm to a viable human embryo, thus
avoiding serious ethical questions that surround other areas of stem
cell research. hpSC possess unique immune-matching attributes making
them an excellent platform for the development of cellular therapies for
large populations of individuals. As of today, ISCO has successfully
derived ten hpSC lines. One of these lines carries the most common
immune type found within the US population and can be immune-matched to
an estimated 75 million people worldwide.
"The commercial launch of the new skin care products represents an
important step in the execution of ISCO's strategy. The revenue
generated from sales will help support the development of our
therapeutic programs utilizing our unique and powerful class of human
pluripotent stem cells," said Dr. Ruslan Semechkin, CEO of Lifeline Skin
Care.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent human
stem cells from unfertilized oocytes (eggs). These proprietary cells
avoid ethical issues associated with use or destruction of viable human
embryos and, unlike most other major stem cell types, can be immune
matched and be a source of therapeutic cells with minimal rejection
after transplantation into hundreds of millions of individuals of
differing racial groups. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary, Lifeline Cell Technology, and is developing a line of
cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is
advancing novel human stem cell-based therapies where cells have been
proven to be efficacious but traditional small molecule and protein
therapeutics have not. More information is available on ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated developments, product introduction
plans, the potential benefits of planned products, collaborations,
affiliations, and other opportunities for the company and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products and the management of
collaborations, regulatory approvals, need and ability to obtain future
capital, application of capital resources among competing uses, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update forward-looking statements.
Key Words: Stem cells, parthenogenesis, biotechnology, skin care,
anti-aging
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 1-760-940-6383 kaldrich@intlstemcell.com or Lifeline
Skin Care, Inc. Ruslan Semechkin, PhD, President & CEO Vice
President, ISCO ras@intlstemcell.com |